MX2022003100A - Un inmunoterapeutico para el tratamiento del cancer de prostata. - Google Patents
Un inmunoterapeutico para el tratamiento del cancer de prostata.Info
- Publication number
- MX2022003100A MX2022003100A MX2022003100A MX2022003100A MX2022003100A MX 2022003100 A MX2022003100 A MX 2022003100A MX 2022003100 A MX2022003100 A MX 2022003100A MX 2022003100 A MX2022003100 A MX 2022003100A MX 2022003100 A MX2022003100 A MX 2022003100A
- Authority
- MX
- Mexico
- Prior art keywords
- gnrh
- therapeutic agent
- peptide
- therapeutic
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899553P | 2019-09-12 | 2019-09-12 | |
| PCT/US2020/050194 WO2021050722A1 (en) | 2019-09-12 | 2020-09-10 | An immunotherapeutic for prostate cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003100A true MX2022003100A (es) | 2022-04-06 |
Family
ID=74867215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003100A MX2022003100A (es) | 2019-09-12 | 2020-09-10 | Un inmunoterapeutico para el tratamiento del cancer de prostata. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220339238A1 (https=) |
| EP (2) | EP4028043A4 (https=) |
| JP (2) | JP7677953B2 (https=) |
| KR (1) | KR20220062080A (https=) |
| CN (1) | CN114599387A (https=) |
| AU (1) | AU2020346818A1 (https=) |
| BR (1) | BR112022004477A2 (https=) |
| CA (1) | CA3152055A1 (https=) |
| MX (1) | MX2022003100A (https=) |
| WO (1) | WO2021050722A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7677953B2 (ja) * | 2019-09-12 | 2025-05-15 | ヘキサマー・セラピューティクス・インコーポレイテッド | 前立腺癌処置のための免疫治療薬 |
| US20230346920A1 (en) * | 2020-05-04 | 2023-11-02 | Hexamer Therapeutics, Inc. | Vaccines against viral pathogens |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
| JP7837616B2 (ja) * | 2025-07-25 | 2026-03-31 | 株式会社大都技研 | 遊技台 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
| WO1997015316A1 (en) * | 1995-10-27 | 1997-05-01 | Merck & Co., Inc. | Conjugates of gonadotropin releasing hormone |
| US6319503B1 (en) * | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| CU23204A1 (es) * | 2002-12-27 | 2007-05-18 | Ct Ingenieria Genetica Biotech | Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias |
| CU23739A1 (es) * | 2008-09-30 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno |
| WO2015164798A1 (en) * | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| AU2016419048B2 (en) * | 2016-08-11 | 2024-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| MA52591A (fr) * | 2018-07-12 | 2021-06-02 | Hexamer Therapeutics Inc | Échafaudage peptidique autoassemblé |
| JP7677953B2 (ja) * | 2019-09-12 | 2025-05-15 | ヘキサマー・セラピューティクス・インコーポレイテッド | 前立腺癌処置のための免疫治療薬 |
| US20230346920A1 (en) * | 2020-05-04 | 2023-11-02 | Hexamer Therapeutics, Inc. | Vaccines against viral pathogens |
-
2020
- 2020-09-10 JP JP2022516126A patent/JP7677953B2/ja active Active
- 2020-09-10 CA CA3152055A patent/CA3152055A1/en active Pending
- 2020-09-10 US US17/753,663 patent/US20220339238A1/en active Pending
- 2020-09-10 WO PCT/US2020/050194 patent/WO2021050722A1/en not_active Ceased
- 2020-09-10 EP EP20863353.7A patent/EP4028043A4/en active Pending
- 2020-09-10 AU AU2020346818A patent/AU2020346818A1/en active Pending
- 2020-09-10 CN CN202080062776.XA patent/CN114599387A/zh active Pending
- 2020-09-10 BR BR112022004477A patent/BR112022004477A2/pt unknown
- 2020-09-10 EP EP22203434.0A patent/EP4183417A1/en active Pending
- 2020-09-10 KR KR1020227012108A patent/KR20220062080A/ko active Pending
- 2020-09-10 MX MX2022003100A patent/MX2022003100A/es unknown
-
2025
- 2025-05-01 JP JP2025076282A patent/JP2025124645A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022004477A2 (pt) | 2022-05-31 |
| JP2025124645A (ja) | 2025-08-26 |
| CN114599387A (zh) | 2022-06-07 |
| WO2021050722A1 (en) | 2021-03-18 |
| CA3152055A1 (en) | 2021-03-18 |
| EP4028043A1 (en) | 2022-07-20 |
| EP4028043A4 (en) | 2023-08-02 |
| EP4183417A1 (en) | 2023-05-24 |
| US20220339238A1 (en) | 2022-10-27 |
| JP7677953B2 (ja) | 2025-05-15 |
| JP2022548050A (ja) | 2022-11-16 |
| KR20220062080A (ko) | 2022-05-13 |
| AU2020346818A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003100A (es) | Un inmunoterapeutico para el tratamiento del cancer de prostata. | |
| CL2021002669A1 (es) | (divisional de solicitud 3443-2018) tratamientos de cancer. | |
| AR110567A1 (es) | Conjugados específicos de anticuerpo-principio activo (adcs) con inhibidores de ksp (proteína del hueso de la quinecina) | |
| CO6180466A2 (es) | Composiciones y metodos para diagnosticar y tratar cancer | |
| MX2021001517A (es) | Terapia basada en microarn dirigida contra canceres positivos para proteina citosolica de linfocito 1 (lcp-1). | |
| PE20251185A1 (es) | Proteinas de union condicionalmente activadas restringidas | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| AR084053A1 (es) | Agente terapeutico que induce citotoxicidad | |
| CO6180469A2 (es) | Anticuerpos anti-epha2 | |
| ES2691091T3 (es) | Vacuna conjugada de péptido antigénico de WT1 | |
| AR091218A1 (es) | Agente terapeutico o agente profilactico para los trastornos cognitivos | |
| MX2020004712A (es) | Vesiculas extracelulares modificadas geneticamente con proteinas. | |
| ECSP099276A (es) | Agente para prevenir/tratar el cancer | |
| PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| AR080663A1 (es) | Proteinas de union especificas y sus usos | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
| PE20131411A1 (es) | Anticuerpos contra la tweak humana y usos de los mismos | |
| PE20081004A1 (es) | Agentes inductores de muerte celular | |
| JOP20190103A1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| MX2016008072A (es) | Compuestos al receptor-3 del factor de crecimiento del fibroplasto (fgfr3) y metodos de tratamiento. |